Aytu BioPharma, Inc. develops and commercializes prescription medicines focused on complex central nervous system diseases. Its recurring company updates center on EXXUA (gepirone) extended-release tablets, an FDA-approved selective serotonin 5HT1a receptor agonist for major depressive disorder in adults, along with its ADHD products and legacy pediatric portfolio.
News from Aytu also covers operational and financial results, commercial launch activity, retail and Aytu RxConnect patient-access distribution, investor presentations, and product-level clinical and safety information for EXXUA. The company is a Nasdaq-listed specialty pharmaceutical issuer with prescription products sold through commercial distribution channels.
Aytu BioPharma (NASDAQ:AYTU) announced the U.S. FDA has granted Orphan Drug designation to AR101 (enzastaurin) for treating vascular Ehlers-Danlos Syndrome (VEDS), a rare genetic disorder with no FDA-approved treatments. This designation allows for financial incentives and potential market exclusivity. The company plans to initiate the pivotal PREVEnt Trial for AR101 in early 2022, aimed at addressing the unmet medical needs of VEDS patients. CEO Josh Disbrow emphasized the significance of this milestone for future therapeutic developments.
Aytu BioPharma has received a U.S. patent for its Healight ultraviolet-A light-based respiratory catheter, enabling treatment of infectious conditions via a UV-light-emitting delivery tube. Patent Number 11,179,575, extending to August 2040, covers innovative methods of internal treatment. CEO Josh Disbrow highlighted the patent's broad implications, allowing applications beyond endotracheal use. The Healight device aims to treat severe respiratory infections, specifically targeting SARS-CoV-2, and shows promising results in small clinical studies.
Aytu BioPharma, Inc. (NASDAQ:AYTU) announced its recognition as the 178th fastest-growing company in North America by the Deloitte Technology Fast 500, demonstrating a remarkable 758% growth from 2017 to 2020. This accolade reflects Aytu's evolution into a fully integrated pediatric-focused specialty pharmaceutical company. CEO Josh Disbrow highlighted the company's strategic milestones and ongoing commitment to developing innovative therapeutic solutions. Aytu's commercial portfolio includes treatment for ADHD and other pediatric conditions, along with a developing pipeline for rare diseases.
Aytu BioPharma reported a strong fiscal Q1 2022, with net revenues of $21.9 million, a 62% increase year-over-year. The company experienced a significant rise in prescription revenues, particularly in its ADHD product line, which grew 140%. Despite this growth, Aytu posted a net loss of $27.9 million, largely due to a $19.5 million impairment expense. Aytu ended the quarter with $40.6 million in cash and plans a pivotal study for AR101 in VEDS, expected to start in early 2022.
Aytu BioPharma (NASDAQ:AYTU) announced a conference call on November 15, 2021, at 4:30 p.m. ET for reviewing its first quarter fiscal 2022 results and discussing its business strategy. The company will also file its Form 10-K after market close on the same day. The call can be accessed via toll-free and international numbers, with a replay available for fourteen days. Aytu specializes in therapeutics for ADHD and has a growing product portfolio, including treatments for pediatric conditions.
Summary not available.
Aytu BioPharma reported a 74% sequential increase in net revenue to $23.5M for the fourth quarter and 138% year-over-year growth to $65.6M for fiscal 2021. The company ended the quarter with approximately $50M in cash. A pivotal study for AR101, targeting Vascular Ehlers-Danlos Syndrome, is set to begin in early 2022. The merger with Neos Therapeutics is expected to generate $15M in annual synergies. However, the company reported a net loss of $19M in Q4 and $58.3M for the year due to acquisition-related expenses and impairment charges.
Aytu BioPharma (NASDAQ:AYTU) will host a conference call on September 27, 2021, at 4:30 p.m. ET to discuss its fourth quarter and fiscal year 2021 achievements.
The call will provide insights into the company's business strategy and growth plans. Aytu will file its Form 10-K prior to market opening on September 28, 2021, ensuring investors have timely access to financial results.
Key products include medications for ADHD and a developmental pipeline targeting rare diseases.
Aytu BioPharma (NASDAQ:AYTU) announced the formation of a Scientific Advisory Board (SAB) chaired by Dr. Hal Dietz, an expert in genetic disorders. The SAB aims to guide the development of AR101 (enzastaurin), an investigational treatment for Vascular Ehlers-Danlos Syndrome (VEDS), a rare genetic condition with no approved therapies. Initial members include renowned experts from leading institutions worldwide, who will provide insights to minimize clinical risks and advance AR101's pivotal studies. The company emphasizes that strong leadership from the SAB is vital as it seeks to enhance treatment options for VEDS patients.
Aytu BioPharma (NASDAQ:AYTU) announced that its CEO Josh Disbrow will present at two investor conferences in September 2021. The first presentation is at the H. C. Wainwright 23rd Annual Global Investment Conference, available on demand starting September 13, 2021, at 7 a.m. ET. The second is a live presentation at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 4:40 p.m. ET. Both presentations will be accessible on Aytu's website. Aytu specializes in therapeutics for pediatric conditions and is developing treatments for rare genetic diseases.